SHIPPEO
23.3.2022 11:05:05 CET | Business Wire | Press release
UNILIN , a Belgian manufacturer of flooring, panels and insulation products for the home, has chosen Shippeo , a global leader and European specialist in real-time transportation visibility, to boost service and savings.
Headquartered in Belgium, UNILIN owns 15 powerful brands (including the Quickstep flooring brand) and distributes its products in over 23 countries throughout Europe. The company operates eight key loading sites, consisting of plants, warehouses and a cross dock, and makes over 100,000 deliveries per year to specialised DIY and building supplies retailers via a network of 20 carrier partners.
A lack of visibility of external transport quality, lead times and proof of delivery led UNILIN to look for a solution that would help with supply chain optimisation and the streamlining of processes, thereby improving customer service and enabling the company to stay competitive in its market.
By implementing Shippeo’s real-time transportation visibility solution to collect location data for all deliveries, UNILIN was able to proactively inform customers about potential delays. Shippeo’s advanced ability to track Less-than-Truckload (LTL) was critical, as LTL is UNILIN’s main and most complex transportation method. Shippeo’s solution has been specifically engineered to overcome tracking challenges associated with LTL by using advanced integrations with carriers’ Transportation Management Systems (TMS) and highly accurate geofencing techniques. The live location data captured, along with automatically generated proofs of delivery, is accessible to users on the Shippeo platform portal. Delivery status information provided by Shippeo will also be made available to UNILIN customers via their own customer portal.
Following the success of the first business use case for real-time transportation visibility, UNILIN is now exploring taking advantage of Shippeo’s mobile application for more granular visibility of own fleet shipments thanks to its parcel scanning capabilities.
Shippeo’s Dennis van Bodegom, Director Northern Europe, is thrilled to be working with UNILIN: “Our organisations both share a strong commitment to excellence in service, and I’m sure Shippeo’s real-time visibility and predictive capabilities will lead to an optimised and proactive supply chain, for the benefit of UNILIN as well as their customers.”
Geert van Damme, Transport & Distribution Manager at UNILIN, said: “I did some market studies and a lot of companies came up with ideas. But the only one who could convince me to do a proof of concept was Shippeo. The ability to automatically provide our customers with real-time tracking for all our LTL deliveries is a game changer. The level of data and insight we now have access to also brings much more clarity around our delivery performance.”
About Shippeo (https://www.shippeo.com
)
LinkedIn, Facebook, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
About Unilin (https://www.unilin.com
)
Unilin Group is a global reference for interior design and building. The company engineers, manufactures and markets laminate flooring, luxury vinyl tiles, sheet vinyl, engineered parquet, carpet tiles, broadloom carpet, raw and decorative panels, industrial floors, wall and roof systems and insulation boards. Unilin employs 7.500 people at 105 locations all over the globe, 30 of which are production sites. In 2020, Unilin achieved a turnover of €2.21 billion. Customers and partners know the company as Unilin, IVC or Godfrey Hirst, or through one of its brands, such as Quick-Step, Moduleo, Utherm, Pergo, Evola, Xtratherm or ClicWall. Unilin Group is proudly part of Mohawk Industries, the world's largest flooring company with a turnover of $ 10 billion and 41.600 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005915/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom